Laboratory tests of a novel serotonin-binding compound have revealed an unexpected disconnect between receptor activation and ...

P silocybin—the psychedelic ingredient found in some “magic” mushrooms—has shown a lot of promise for treating depression and ...

Serotonergic psychedelics, such as psilocybin and LSD, are also commonly referred to as hallucinogens because at higher "trip-inducing" doses (as opposed to microdoses), these drugs typically trigger ...

Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.

It is becoming increasingly accepted that classic psychedelics like LSD, psilocybin, ayahuasca, and mescaline can act as antidepressants and anti-anxiety treatments in addition to causing ...

Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest research, Treatment with shRNA to ...

Suven Life Sciences Ltd. has identified 5-HT1A receptor agonists and 5-HT2A receptor antagonists reported to be useful for the treatment of depression, insomnia, schizophrenia, bipolar and cognitive ...

This article was originally published on Psychedelic Spotlight and appears here with permission. New study suggests that a non-hallucinogenic LSD analog may hold therapeutic potential for mood ...

The human brain can change — but usually only slowly and with great effort, such as when learning a new sport or foreign language or recovering from a stroke. Learning new skills correlates with ...

Receptors mediate the transmission of information between nerve cells. The release of serotonin alters nerve cell activities throughout the brain. At least 14 types of serotonergic receptors can be ...